Janus kinase inhibitors

Janus Kinase Inhibitors: Transforming Treatment Paradigms in Lymphomas and Immune-Mediated Complications

By MedXY 08/26/2026

Janus kinase inhibitors have emerged as pivotal agents in managing lymphoid malignancies and associated immune complications, offering new therapeutic avenues shaped by molecular insights into the JAK/STAT pathway.

Allergy & Immunology Dermatology news

Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering Strategies

By MedXY 07/12/2026

This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their impact on efficacy, safety, and cost.

Clinical Updates news Rheumatology Specialties

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.